Edition:
United Kingdom

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

2.54USD
17 Aug 2018
Change (% chg)

$-0.06 (-2.31%)
Prev Close
$2.60
Open
$2.60
Day's High
$2.63
Day's Low
$2.48
Volume
181,059
Avg. Vol
132,396
52-wk High
$6.71
52-wk Low
$2.35

Chart for

About

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $478.08
Shares Outstanding(Mil.): 83.43
Dividend: --
Yield (%): --

Financials

  ELGX.OQ Industry Sector
P/E (TTM): -- 32.30 32.76
EPS (TTM): -0.94 -- --
ROI: -23.25 13.94 14.61
ROE: -64.43 16.79 16.33

BRIEF-Endologix Reports Q1 Loss Per Share $0.24

* Q1 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S

02 May 2018

BRIEF-Endologix Appoints John Onopchenko As Chief Executive Officer

* ENDOLOGIX APPOINTS JOHN ONOPCHENKO AS CHIEF EXECUTIVE OFFICER

02 May 2018

BRIEF-Endologix Reports Positive Results From Global Encore Analysis With Polymer Endovascular Aneurysm Repair

* ENDOLOGIX INC - POSITIVE RESULTS FROM GLOBAL ENCORE ANALYSIS WITH POLYMER ENDOVASCULAR ANEURYSM REPAIR USING OVATION ABDOMINAL STENT GRAFT SYSTEMS Source text for Eikon: Further company coverage:

19 Mar 2018

BRIEF-Endologix Inc CEO John McDermott Steps Down

* JOHN MCDERMOTT STEPS DOWN AS CHIEF EXECUTIVE OFFICER OF ENDOLOGIX, INC.

21 Feb 2018

BRIEF-Endologix Posts Q4 Loss Per Share $0.17

* ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

21 Feb 2018

Competitors

Earnings vs. Estimates